Listed by the USPTO as ANDERSON, REBECCA L
Tech Center 1600 • Art Units: 1626
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18569721 | TREATMENT AND PREVENTION OF DEVELOPMENTAL DISORDERS AND MENTAL DISEASES | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, |
| 18532632 | TREATMENT OF MYELOPROLIFERATIVE DISEASES AND DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17790407 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Non-Final OA | The Regents of the University of California |
| 17570997 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | Final Rejection | The Regents of the University of California |
| 19661115 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | Non-Final OA | Compass Pathfinder Limited |
| 19629952 | PREPARATION OF PSILOCYBIN, DIFFERENT POLYMORPHIC FORMS, INTERMEDIATES, FORMULATIONS AND THEIR USE | Final Rejection | Compass Pathfinder Limited |
| 19110241 | SPRAY-DRIED AMORPHOUS SOLID DISPERSIONS AND METHOD FOR PREPARATION | Non-Final OA | Merck Patent GMbH |
| 18767505 | ARYLQUINAZOLINES | Non-Final OA | Merck Patent GmbH |
| 18215286 | INHIBITORS OF TRIM33 AND METHODS OF USE | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 18288473 | MELANIN MATERIALS FOR TISSUE REPAIR | Non-Final OA | Northwestern University |
| 18845807 | NOVEL PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITOR, COMPOSITIONS COMPRISING THE SAME, METHODS OF MAKING, AND METHODS OF TREATING A DISEASE | Non-Final OA | The Curators of the University of Missouri |
| 18864008 | 5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE | Non-Final OA | CHINA PHARMACEUTICAL UNIVERSITY |
| 18035502 | NOVEL VHL SMALL MOLECULE PROBES | Non-Final OA | St. Jude Children's Research Hospital, Inc. |
| 18278166 | COMPOSITION COMPRISING BETA BLOCKER AND CHOLINESTERASE INHIBITOR FOR TREATMENT OF NEURODEGENERATIVE DISEASE | Final Rejection | DR. NOAH BIOTECH INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy73.5% of resolved applications examined by Rebecca L Anderson were allowed (1,055 resolved cases), compared with 54.6% across Art Unit 1626 over the last five years.
This examiner's interview lift is +23.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Rebecca L Anderson took 855 days on average from filing to allowance.
Rebecca L Anderson examines applications in Art Unit 1626 in Tech Center 1600 (Biotechnology & Pharmaceuticals).